SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq:SOPH) has commenced a proposed underwritten public offering of ordinary shares. The company plans to grant underwriters an option to buy up to an additional 15% of the shares at the offering price, less underwriting discount.

All shares will be newly issued by the company, with size, price and timing dependent on market and other conditions. TD Cowen is lead book-running manager. The offer will be made under an effective SEC Form F-3 shelf registration and will not be publicly offered or listed in Switzerland.

Positive

• Proposed underwritten public offering could raise new equity capital
• Underwriters’ 15% option may increase total capital raised if exercised
• Effective Form F-3 shelf registration provides financing flexibility

Negative

• New share issuance is likely to dilute existing SOPH shareholders
• Offering size, terms and completion remain uncertain and market-dependent

News Market Reaction – SOPH

+6.29% 2.0x vol

8 alerts

+6.29% Session close to close

+21.8% Peak in 17 hr 35 min

$393.41M Market Cap

2.0x Rel. Volume

In the Jun 17 session, SOPH gained 6.29%, reflecting a notable positive market reaction. Argus tracked a peak move of +21.8% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the stock’s position near its 52-week high and above its 200-day MA. Investors previously reacted inconsistently to partnerships and earnings, so enthusiasm around an offering could reflect confidence in capital deployment. However, existing shelf capacity and the new primary raise both represent potential dilution sources, and any rally could be sensitive to final deal size, pricing, and follow-on execution risks.

Key Figures

Underwriters’ option size: 15% additional ordinary shares

1 metrics

Underwriters’ option size 15% additional ordinary shares Potential over-allotment option in the proposed underwritten public offering

Historical Context

5 past events · Latest: Jun 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 10	Leadership transition	Neutral	-3.3%	Management reorganization ahead of 2026 AGM and CEO transition.
Jun 04	Strategic partnership	Positive	+3.8%	MOU for precision oncology joint venture with major cancer center.
May 13	Commercial partnership	Positive	-2.6%	Blood-based cancer testing collaboration to expand UK patient access.
May 05	Quarterly earnings	Neutral	-4.2%	Q1 2026 results with revenue growth and ongoing adjusted EBITDA losses.
Apr 21	Earnings date notice	Neutral	-1.4%	Announcement of timing and webcast details for Q1 2026 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions: one strategic partnership drew a positive move, another a decline, while earnings and governance updates saw modest negative trading, suggesting inconsistent alignment between news tone and price action.

Recent Company History

Over the past few months, SOPH has reported several strategic and financial updates. On May 5, 2026, Q1 2026 results showed revenue of $21.7M with an adjusted EBITDA loss, and the stock fell 4.16%. Partnerships announced on May 13 and June 4, 2026 generated mixed reactions, with moves of -2.59% and +3.77%. A leadership transition disclosed on June 10, 2026 coincided with a -3.33% move. Today’s proposed offering follows this period of strategic expansion and governance change.

Key Terms

underwritten public offering, registration statement, form f-3, prospectus supplement, +1 more

5 terms

underwritten public offering financial

"announced today the commencement of a proposed underwritten public offering of its ordinary"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

registration statement regulatory

"A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

form f-3 regulatory

"A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"The offering may be made only by means of a prospectus supplement relating to such offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

six swiss exchange regulatory

"these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on"

A national stock exchange that operates the primary marketplace for buying and selling shares and other securities in Switzerland. Think of it as a regulated auction house where prices are visible, trades are matched, and listing rules and disclosure standards help ensure orderly markets; its listings, trading volume and rules matter to investors because they affect how easily shares can be bought or sold, how transparent pricing is, and the credibility of listed companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  

TD Cowen is acting as the lead book-running manager for the offering.

A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares and other securities of the Company has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 15, 2025. The offering may be made only by means of a prospectus supplement relating to such offering and the accompanying prospectus. The preliminary prospectus supplement for the offering and the accompanying prospectus will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of SOPHiA GENETICS SA, such as the ordinary shares, in or into Switzerland within the meaning of the Swiss Financial Services Act ("FinSA") and these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland. Neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, may be publicly distributed or otherwise made publicly available in Switzerland.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed underwritten public offering including the size, timing and structure of the proposed offering and the completion of the proposed offering on the anticipated terms. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear," or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the SEC. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-proposed-public-offering-of-ordinary-shares-302802311.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPHiA GENETICS (SOPH) announce on June 16, 2026 about its stock?

SOPHiA GENETICS announced a proposed underwritten public offering of its ordinary shares. According to SOPHiA GENETICS, all shares in the deal will be sold by the company, potentially increasing its equity capital base if market conditions allow completion.

How large is the SOPHiA GENETICS (SOPH) June 2026 stock offering and what is the 15% option?

The company has not disclosed the base size or price of the offering. According to SOPHiA GENETICS, underwriters are expected to receive an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less underwriting discount.

Who is managing the SOPHiA GENETICS (SOPH) proposed public offering of ordinary shares?

TD Cowen is acting as the lead book-running manager for the SOPHiA GENETICS offering. According to SOPHiA GENETICS, the transaction is under an effective SEC Form F-3 shelf registration, and completion depends on market and other conditions.

What does the June 2026 SOPHiA GENETICS (SOPH) offering mean for existing shareholders?

The deal would add new shares, which typically dilutes existing holdings. According to SOPHiA GENETICS, all shares are newly issued by the company, with final size, pricing and completion still subject to market and other conditions.

Can investors in Switzerland participate in the SOPHiA GENETICS (SOPH) June 2026 offering?

The announcement specifies there is no intention to publicly offer the shares in Switzerland. According to SOPHiA GENETICS, the securities will not be listed on SIX Swiss Exchange or other Swiss regulated trading venues.

Under which SEC registration is the SOPHiA GENETICS (SOPH) stock offering being made?

The offering uses an effective shelf registration on Form F-3. According to SOPHiA GENETICS, the registration statement was declared effective on August 15, 2025, and sales will occur only via a prospectus supplement and accompanying prospectus.